Program
JS1-1-01 high-dose group
Its studies are mostly in Depression, led by China Resources Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| China Resources Pharmaceutical Group | 21 open or running | phase 3since Mar 16, 2026 | Feb 6, 2024 | Dec 31, 2026phase 3 · NCT07485595 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 6, 2024First study: phase 2 study in DepressionFirst studyNCT06259526 · 267 enrolled · China
- Mar 16, 2026Phase 3 study in DepressionPhase 3 reachedNCT07485595 · 180 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in DepressionNCT07485595
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07485595Depression · China | 3 | Not yet recruiting | Dec 31, 2026 | 180 |
| NCT06259526Depression · China | 2 | Completed | Oct 23, 2024 | 267 |
How it is read
Names in the registry
- “JS1-1-01 high-dose group”, 2 entries
Conditions, from the studies’ own filings
- Depression, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.